Archive for the ‘Crispr’ Category

1. FDA OKs first-ever use of gene-editing tool CRISPR to tackle Covid-19  Boston Business Journal
2. Feng Zhang's Sherlock gets first-ever CRISPR nod as FDA green-lights Covid-19 test kit  MedCity News
3. FDA Authorizes First-Ever Crispr Application For COVID-19 Coronavirus Test  Forbes
4. A COVID-19 diagnostic that uses CRISPR gets a nod from the FDA  Chemical & Engineering News
5. FDA authorizes CRISPR-based test for COVID-19  The Verge
6. View Full Coverage on Google News

Read the rest here:
FDA OKs first-ever use of gene-editing tool CRISPR to tackle Covid-19 - Boston Business Journal

ZUG, Switzerland and CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kimsusan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR617-337-4167reides@wcgworld.com

Go here to read the rest:
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference - Yahoo Finance UK

A team of researchers at the McGovern Institute for Brain Research at MIT, the Broad Institute of MIT and Harvard, the Ragon Institute, and the Howard Hughes Medical Institute (HHMI) has developed a new diagnostics platform called STOP (SHERLOCK Testing in One Pot) COVID. The test can be run in an hour as a single-step reaction with minimal handling, advancing the CRISPR-based SHERLOCK diagnostic technology closer to a point-of-care or at-home testing tool. The test has not been reviewed or approved by the FDA and is currently for research purposes only.

The team began developing tests for COVID-19 in January after learning about the emergence of a new virus which has challenged the healthcare system in China. The first version of the teams SHERLOCK-based COVID-19 diagnostics system is already being used in hospitals in Thailand to help screen patients for COVID-19 infection.

The new test is named STOPCovid and is based on the STOP platform. In research it has been shown to enable rapid, accurate, and highly sensitive detection of the COVID-19 virus SARS-CoV-2 with a simple protocol that requires minimal training and uses simple, readily-available equipment, such as test tubes and water baths.

STOPCovid has been validated in research settings using nasopharyngeal swabs from patients diagnosed with COVID-19. It has also been tested successfully in saliva samples to which SARS-CoV-2 RNA has been added as a proof-of-principle.

The team is posting the open protocol today on a new website, STOPCovid.science. It is being made openly available in line with the COVID-19 Technology Access Framework organized by Harvard, MIT, and Stanford. The Framework sets a model by which critically important technologies that may help prevent, diagnose, or treat COVID-19 infections may be deployed for the greatest public benefit without delay.

There is an urgent need for widespread, accurate COVID-19 testing to rapidly detect new cases, ideally without the need for specialized lab equipment. Such testing would enable early detection of new infections and drive effective test-trace-isolate measures to quickly contain new outbreaks. However, current testing capacity is limited by a combination of requirements for complex procedures and laboratory instrumentation and dependence on limited supplies. STOPCovid can be performed without RNA extraction, and while all patient tests have been performed with samples from nasopharyngeal swabs, preliminary experiments suggest that eventually swabs may not be necessary. Removing these barriers could help enable broad distribution.

The ability to test for COVID-19 at home, or even in pharmacies or places of employment, could be a game-changer for getting people safely back to work and into their communities, says Feng Zhang, a co-inventor of the CRISPR genome editing technology, an Investigator at the McGovern Institute for Brain Research and HHMI, and a Core Institute member at the Broad Institute. Creating a point-of-care tool is a critically important goal to allow timely decisions for protecting patients and those around them.

To meet this need, Zhang, McGovern Fellows Omar Abudayyeh and Jonathan Gootenberg, and colleagues initiated a push to develop STOPCovid. They are sharing their findings and packaging reagents so other research teams can rapidly follow up with additional testing or development. The group is also sharing data on the StopCOVID.science website and via a submitted preprint. The website is also a hub where the public can find the latest information on the teams developments.

STOPCovid is not yet approved by the FDA and is currently being used for research purposes.

How it works

The STOPCovid test combines CRISPR enzymes, programmed to recognize signatures of the SARS-CoV-2 virus, with complementary amplification reagents. This combination allows detection of as few as 100 copies of SARS-CoV-2 virus in a sample. As a result, the STOPCovid test allows for rapid, accurate, and highly sensitive detection of COVID-19 that can be conducted outside clinical laboratory settings.

STOPCovid has been tested on patient nasopharyngeal swab in parallel with clinically-validated tests. In these head-to-head comparisons, STOPCovid detected infection with 97% sensitivity and 100% specificity. Results appear on an easy-to-read strip that is akin to a pregnancy test, in the absence of any expensive or specialized lab equipment. Moreover, the researchers spiked mock SARS-CoV-2 genomes into healthy saliva samples and showed that STOPCovid is capable of sensitive detection from saliva, which would obviate the need for swabs in short supply and potentially make sampling much easier.

The test aims to ultimately be simple enough that anyone can operate it in low-resource settings, including in clinics, pharmacies, or workplaces, and it could potentially even be put into a turn-key format for use at home, says Omar Abudayyeh, McGovern Fellow at the McGovern Institute for Brain Research at MIT.

McGovern Fellow Jonathan Gootenberg adds, Since STOPCovid can work in less than an hour and does not require any specialized equipment, and if our preliminary results from testing synthetic virus in saliva bear out in patient samples, it could address the need for scalable testing to reopen our society.

Importantly, the full test both the viral genome amplification and subsequent detection can be completed in a single reaction, as outlined on the website, from swabs or saliva. To engineer this, the team tested a number of CRISPR enzymes to find one that works well at the same temperature needed by the enzymes that perform the amplification. Zhang, Abudayyeh, Gootenberg and their teams, including graduate students Julia Joung and Alim Ladha, settled on a protein called AapCas12b, a CRISPR protein from the bacterium Alicyclobacillus acidophilus, responsible for the off taste associated with spoiled orange juice. With AapCas12b, the team was able to develop a test that can be performed at a constant temperature and does not require opening tubes midway through the process, a step that often leads to contamination and unreliable test results.

Information sharing and next steps

The team has prepared reagents for 10,000 tests to share with scientists and clinical collaborators for free around the world who want to evaluate the STOPCovid test for potential diagnostic use, and they have set up the website STOPCovid.science to share the latest data and updates with the scientific and clinical community.

To learn more about the STOPCovid technology and point of care nucleic acid testing, visit STOPCovid.science. Kits and reagents can also be requested via a form on the website.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

*This article is based on research findings that are yet to be peer-reviewed. Results are therefore regarded as preliminary and should be interpreted as such. Find out about the role of the peer review process in researchhere. For further information, please contact the cited source.

Read the rest here:
One-step Test Could Provide Rapid and Sensitive COVID-19 Detection - Technology Networks

Something's been brewing in the health care sector, the second-largest group in the S&P 500. Since the start of the second quarter, the Health Care Select Sector SPDR XLV, -0.01% is one of the top asset-gathering exchange traded funds.

The iShares Nasdaq Biotechnology ETF IBB, +0.13%, thanks to plenty of help from Gilead Sciences GILD, +0.18%, is up almost 14% over the past month. Much of the recent biotechnology ebullience is attributable to progress on the coronavirus treatment and vaccine front.

IBB is the largest biotechnology ETF by assets, but it's not the only one delivering impressive returns in recent weeks. Here's a trio of biotech ETFs that are knocking the cover off the ball.

Virtus LifeSci Biotech Clinical Trials ETF (BBC)

The Virtus LifeSci Biotech Clinical Trials ETF BBC, -0.05% tracks the LifeSci Biotechnology Clinical Trials Index. That benchmark is a collection of companies with drugs and therapies in clinical trials, which means BBC is at the right place at the right time in the battle to quash coronavirus.

BBC's holdings are basically equally weighted, but that doesn't distract from the fact that Moderna MRNA, +8.66% is the fund's top holding. Overall, BBC holds about 90 stocks, most of which dwell at the lower end of large-cap territory or are mid- or small-cap names.

In addition to Moderna, several other BBC components have coronavirus treatment exposure and roughly a dozen are credible takeover targets. That's enough to have BBC up nearly 27% over the past month.

ARK Genomic Revolution ETF (ARKG)

In the health care space, the ARK Genomic Revolution ETF (cboe:ARKG) has been one of the best-performing funds for several years, trouncing traditional health care and biotechnology ETFs for several years, speaking to the capabilities of the fund's active managers.

ARKG typically holds 30 to 50 stocks and currently holds 34, several of which are coronavirus plays and that doesn't even begin to underscore the fund's virus detection exposure, which highlights ARKG's deep CRISPR exposure.

As government officials re-open the US, testing for the COVID-19 virus will be a critical step. A new CRISPR-based test called DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) could help speed the process along, ARK analyst Ali Aurman saidin a recent note.

ARKG is higher by nearly 32% over the past month.

Principal Healthcare Innovators Index ETF (BTEC)

The Principal Healthcare Innovators Index ETF BTEC, +0.45% is a departure from the other funds mentioned here because it's not drug/therapy-centric. Rather, BTEC tilts more toward medical device, equipment and life sciences firms.

The fund invests in companies that are leading the charge toward innovative solutions, rather than spending money on marketing and distribution, according to Principal.

BTEC's nearly 210 holdings are considered research and development-intensive companies and the fund's methodology screens out companies with negative or inconsistent earnings. The fund is higher by almost 25% over the past month.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more:
3 Biotech ETFs Up 10% Or More Over The Last Month - MarketWatch

Yield10 Bioscience develops new technologies to increase crop yield in support of a more sustainable food system.

Founded in 1992, the companys focus is metabolic engineering technologies using predictive models to facilitate gene discovery. The aim is to enhance photosynthesis and improve seed and crop yield. The ultimate goal is to make major food crops more productive.

The company is working with a strong pipeline of genetic traits and has achieved initial encouraging yield improvement results in canola, soybean, rice and corn.

According to CEO Dr Oliver Peoples, the biggest gains to be made through CRISPR genome-editing lie in staple food and feed crops.

CRISPR genome-editing can benefit the entire agriculture industry when applied to large acreage of staple food and feed crops such as corn, soybean, canola, rice, wheat, potato and more. Provided the regulatory processes are based on science, genome editing will also be useful in fresh produce crops and for other types of food staples, like cassava and millet, which are important in less developed countries.

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmarks of the bacterial defence system, which forms the basis of CRISPR-Cas genome editing technology.

CRISPR can be used as an advanced plant-breeding tool. It facilitates crop breeding by making cuts at specific locations in a plant genome. Subsequent repair of the cut by the cells endogenous repair mechanism can introduce precise changes.Unlike GMOs, the system works with the native characteristics in the crop and does not introduce new genes. Supporters argue that this means that the biotechnology poses fewer risk factors than GMOs and the process is frequently compared to traditional crop breeding techniques.

Dr Peoples believes that CRISPR will need to be used alongside traditional breeding and GMOs to support food system sustainability. We need traditional breeding, CRISPR and GMO technologies to ensure sustainable global food security, he told FoodNavigator.

In order to feed the estimated 10 billion people by 2050 using the existing land and resources we have available; the agriculture industry needs to incorporate CRISPR genome-editing to enhance crop efficiency.

The key to improving crop genetics has been to use genetic diversity available within a plant species through breeding. By crossing two different plants we are transferring DNA or genes from one plant into the other and then screening to see if that creates a beneficial trait. CRISPR is just a new tool for creating targeted genetic diversity in a crop.

Dr Peoples places these developments in the context of the changing global climate, which brings increased extreme weather events, and the growing population. These factors mean that there is a pressing need to develop new crop varieties that can withstand challenging weather and produce a greater yield on the same amount of land.

The challenges with sustainable food production caused by climate change are due to the unpredictable and variable seasonal weather extremes that farmers are now experiencing. These include drought, flooding, heat and late or early frosts, all of which can have different impacts across even a single growing season. As the average temperature increases, farmers crops also face more pressure from disease and insects.

Using CRISPR genome-edited traits can help make crops more resilient to these weather extremes and disease pressures. The types of genetic traits can be grouped into two key categories; yield traits and stress tolerance traits.

Yield traits focus on photosynthetic efficiency of a crop during the growing season to either protect seed yield under poor growing conditions or to increase the seed yield of a crop, the latter being crucially important to meet the needs of the growing global population.

Stress tolerance traits help increase a crops resiliency such that yields are not reduced by environmental stressors often associated with climate change such as heat, cold, drought and flooding. Each of these types of traits have a common goal and that is to protect food production so incorporating both, not just one or the other, will be key to overcoming challenging growing seasons stemming from climate change and meeting food security demands.

Traditional plant breeding techniques have been used for thousands of years in crop cultivation. Gene editing offers two key advantages: speed and precision.

Plant breeding for new or improved traits like drought tolerance requires access to new genetic diversity in the form of different DNA sequences. Breeders have used many techniques to create that genetic diversity including radiation and chemical mutagenesis in their breeding programs.

CRISPR genome-editing is a precise plant breeding technique and accelerates the trait development process by activating and suppressing very specific genes in the plant DNA in a highly precise and targeted way. This means its a faster, more efficient approach to create crops with ideal traits such as increased yield and resilience.

Dr Peoples argued that CRISPR and indeed genetic engineering are more precise and even safer than some traditional plant breeding methods, such as radiation mutagenesis.

GMOs have been poorly received by European regulators and significantly consumers. Unlike CRISPR, genetic modification works by introducing new DNA to plants.

Dr Peoples believes that GMOs are an important piece of the toolbox for delivering food security and, again, he compares the techniques used to more orthodox agricultural methods. Take for example the use of pest resistance genes from bacteria, which were introduced into crops to make them insect resistant. This is basically the equivalent to vaccinating the plant, so it has immunity to the pest. The same genes and resistance proteins are used extensively in organic farming by spraying them onto the plants. GMO is simply a more efficient process for accomplishing the same goal which is to protect the crop from insects.

Nevertheless, European regulators take a relatively tough stance on controlling GMOs, the definition of which includes CRISPR techniques.

Dr Peoples said he believes this stance to be politically and economically driven rather than based on the scientific facts. First, there is not a single crop grown in the EU that has not been developed using some form of genetic engineering. Crossing different varieties of plant is, after all, the basis of plant breeding and the purpose is to take DNA from one variety and introduce it into the other using sexual crossing.

The anti-GMO stance of the EU is driven primarily by misinformation to the public from NGOs and market protectionism to sustain the EUs common agricultural policy. The EU imports large quantities of GMO soybean meal from both North and South America for animal feed, so where they have a need, they adapt and follow the science.

He also took aim at Europes controversial decision to lump CRISPR gene editing into its definition of GMOs. I dont believe theres a clear misunderstanding of what CRISPR genome-editing is and how it differs from genetic modification. The EU regulatory bodies have been educated about these differences. In fact, the EU regulatory body initially took the position that CRISPR genome editing is different from genetic modification before pressures from anti-GMO groups drove a 2019 EU court ruling blocking this position.

Dr Peoples suggested that little can be done to win over these anti-GMO lobbyists. I doubt that it matters to these groups which form of genetic engineering is used. Their business model centers around a firm anti-genetic engineering or GMO stance, so the scientific facts dont matter as much as staying on message.

However, he said that the public mood towards gene editing appears to be shifting: Thanks to new advancements and education around this technology, more everyday consumers are embracing CRISPR genome editing. Since this technique uses a plants existing DNA, it feels closer to the traditional breeding techniques, appears safer and doesnt warrant the same backlash as GM.

In order to support this shift, the scientific community is pushing back against the anti-GMO rhetoric to spotlight the economic, health, social and environmental benefits of CRISPR genome-editing.

In the EU, EASAC, the voice of independent science advice, has called for radical reform of EU legislation around GMOs noting that current regulations are no longer fit for purpose.

Efforts to communicate and educate are vital to gaining support, Dr Peoples suggested. Progress has been made but in order to create a substantial impact, the scientific community needs to continue working with various governments and regulatory bodies to educate consumers and legislators about the benefits these breeding techniques can offer.

Dr Peoples also suggested that attitudes towards the use of science in food are being shaped by external events. Necessity, it would seem, not only proves the mother of invention but also of acceptance.

Minimizing the effects of climate change and creating a healthier, more sustainable lifestyle are two key factors weighing heavily on genetically engineered crop acceptance. For example, the plant-based meat trend has been advertised as a healthier, more environmentally friendly alternative to traditional meat, and some of these plant-based substitutes have been developed using GMO products.

For millennials, climate change and sustainability are their key decision drivers and they are more open to technology in general. Many are not vested in the anti-GMO falsehoods which sustained the entire careers of anti GMO activists before evolving into a negative marketing tool. Were living in a time where consumer decisions are driven by their social, economic, environmental and health interests.

The current coronavirus crisis the first global pandemic since the 1918 Spanish flu has led to people feeling threatened physically and economically by the COVID-19 virus. This, too, is making people more open to science-based solutions.

Now more than ever we are looking to science for solutions and the specific scientific method or tool for creating that solution simply does not matter. The third-generation vaccine developed by the Canadian Government and Merck for Ebola is a great example of the power of genetic engineering tools and the benefits to humanity of a GMO product. Work is underway at the University of Oxford in the UK and probably elsewhere to develop a COVID-19 vaccine using a similar approach.

However, Dr Peoples added, there are limits: For the first time in many decades the availability of food is once more a question. The availability of an effective vaccine will not change the minds of many anti-vaxers just like the use of new genetic engineering tools wont change the minds of anti-GMO activists.

Follow this link:
CRISPR genome editing to address food security and climate change: 'Now more than ever we are looking to science for solutions' - FoodNavigator.com

ZUG, Switzerland and CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kimsusan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR617-337-4167reides@wcgworld.com

The rest is here:
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference - Yahoo Finance

Wide-spread testing has long been the Achilles' heel of the U.S. response efforts. Shortages, false negatives, and inaccurate kits have plagued efforts to provide quick and easy results to Americans. But scientists hope a new test can be the answer to that problem. In other testing news: antibody tests, false negatives and states' ongoing efforts to ramp up screenings.

The New York Times:With Crispr, A Possible Quick Test For The CoronavirusA team of scientists has developed an experimental prototype for a fairly quick, cheap test to diagnose the coronavirus that gives results as simply as a pregnancy test does. The test is based on a gene-editing technology known as Crispr, and the researchers estimated that the materials for each test would cost about $6. Were excited that this could be a solution that people wont have to rely on a sophisticated and expensive laboratory to run, said Feng Zhang, a researcher at the Broad Institute in Cambridge, Mass., and one of the pioneers of Crispr technology. (Zimmer, 5/5)

ABC News:Roche CEO Severin Schwan Says Producing New Antibody Test Part Of Busiest Time In His CareerSeverin Schwan, the CEO of Swiss drugmaker Roche, says employees from across the company are coming together to contribute to meeting the aggressive manufacturing targets the company has promised after receiving emergency Food and Drug Administration approval for its COVID-19 antibody test on Sunday. "I mean, even in the packaging lines, we have our employees who come from all over the place, who raised their hand and who say ... 'Can I help out in the warehouse?'" Schwan said in an interview with ABC News. "The engagement is -- and the commitment and the passion is -- really enormous. I can't tell you how proud I am of the organization and how they excel during this difficult, unprecedented time." (Bolton, 5/5)

Boston Globe:Walthams PerkinElmer Gets Emergency Approval For COVID-19 Antibodies TestPerkinElmer, the Waltham-based diagnostics maker, said Tuesday that a subsidiary has obtained an "emergency use authorization from the Food and Drug Administration for a test that detects antibodies in the blood of people who fought off COVID-19. The test made by EUROIMMUN, a subsidiary based in Lubeck, Germany, is one of a dozen made by different companies that have won such approvals, according to the FDA website. (Saltzman, 5/5)

Cincinnati Enquirer:COVID-19: Who's At Fault When A Negative Test Is False? Maybe NobodyWhen a Hyde Park woman was tested for COVID-19 and the test came back negative despite her symptoms, she was perplexed, disappointed and anxious. She was clearly sick and doctors ultimately decided to treat her. So who was at fault? Maybe nobody. That's because even a good test can end in a bad or faulty result. Improving test reliability is important, as Ohio, Kentucky and other states start to loosen restrictions on business and rely on tests to find people who need treatment. (Mitchell, 5/5)

Politico:Bubble Bursts On Cuomos Hope Of 'Immunity' TestingAs his state was being ravaged by the worst coronavirus outbreak in the country in early April, Gov. Andrew Cuomo offered a glimpse of hope to those looking for a quick restart of New Yorks economy: An antibody test, developed in a state laboratory, may be able to confirm immunity for a vast number of New Yorkers. By last week, Cuomo and other officials had retreated from the approach, pointing instead to other metrics that may indicate the best way to avoid future waves of the virus. Cuomo is now describing the immunity idea as little more than a theory. (Gronewold and Young, 5/5)

WBUR:Florida Boosts COVID-19 Testing, Sending New-Case Rate To A Record LowFlorida Gov. Ron DeSantis says his state has hit a new record low in the rate of positive test results for COVID-19, as only around 2.5% of nearly 24,000 tests confirmed an infection on Monday. The test results were the most Florida has received in a single day. The governor celebrated the good news, which emerged one day after Florida relaxed shutdown restrictions on restaurants and retail stores in much of the state. (Chappell, 5/5)

Read more:
Utilizing CRISPR, Scientists Develop Prototype For Coronavirus Test That Could Be As Quick, Easy As A Pregnancy One - Kaiser Health News

New Delhi: Scientists from Delhi based-Institute of Genomics and Integrative Biology (IGIB) would work together with Tata Sons to develop Indias first paper-strip test for rapid diagnosis of Covid-19.

The premier CSIR laboratory has signed a Memorandum of Understanding (MoU) with Tata Sons for licensing of know-how and scaling up the technology in the form a kit which can be deployed for Covid-19 testing on the ground by the end of May.

The testing approach was developed by a team led by scientists, Dr Souvik Maiti and Dr Debjyoti Chakraborty from CSIR-IGIB in early April and named Feluda - FNCAS9 Editor Linked Uniform Detection Assay (Feluda), after a famous fictional character that appeared in short stories written by noted filmaker Satyajit Ray.

The test uses cutting-edge, futuristic gene-editing tool- Crispr-Cas9 to target and identify the genomic sequences of the novel coronavirus in the samples of suspected individuals.

The technology was conceived and developed at CSIR IGIB under sickle cell mission and utilizes an indigenously developed cutting edge CRISPR Cas9. A combination of CRISPR biology and paper-strip chemistry leads to a visible signal readout on a paper strip that can be rapidly assessed for confirming the presence of viral infection in a sample," said Dr Anurag Aggarwal, Director, IGIB, New Delhi.

Unlike the real time PCR test currently used for diagnosis of Covid-19 in India, costing about 4500, this test would be affordable, since it does not depend on expensive real-time PCR machines which are already in limited supply.

We are happy to enter into a partnership with IGIB for further development and commercialization of this CRISPR based technology for COVID-19 detection. It uses a test protocol that is simple to administer and easy to interpret enabling results to be made available to the medical fraternity in relatively lesser time, as compared to other test protocols," said Banmali Agrawala, President - Infrastructure and Defence and Aerospace, Tata Sons.

The kit is similar to a portable paper-strip test used to confirm pregnancy and does not require any specialized tools or different skills to operate.

Unlike most rapid tests which require dedicated machinery, it can be performed using simple standard equipments available in any pathological laboratory.

It is also the first such indigeneous testing kit based on Crisper technology to be developed in India.

Go here to see the original:
Covid-19: CSIR-IGIB partner with TATA Sons to make Indias first paper-strip kit - Livemint

Within the last decades, new genetic engineering tools for manipulating genetic material in plants, animals and microorganisms are getting large attention from the international community, bringing new challenges and possibilities. While genetically modified organisms (GMO) have been known and used for quite a while now, gene drive organisms (GDO) are yet at the consideration and evaluation stage.

The difference between these two technologies, where both are meant to replace certain characters in animals or plants with ones that are more favourable for the human population, is that, even though in GDO there is also foreign "synthetic" DNA being introduced, the inheritance mode differs. In GDO, the genome's original base arrangements are changed, using CRISPR/Cas-9 genome editing. Once the genome is changed, its alterations are carried down the organism's offspring and subsequent generations.

In their study, published in the open-access journal BioRisk, an international group of scientists led by Marion Dolezel from the Environment Agency Austria, discuss the potential risks and impacts on the environment.

The research team also points to current regulations addressing invasive alien species and biocontrol agents, and finds that the GMO regulations are, in principle, also a useful starting point for GDO.

There are three main areas suggested to benefit from gene drive systems: public health (e.g. vector control of human pathogens), agriculture (e.g. weed and pest control), environmental protection and nature conservation (e.g. control of harmful non-native species).

In recent years, a range of studies have shown the feasibility of synthetic CRISPR-based gene drives in different organisms, such as yeast, the common fruit fly, mosquitoes and partly in mammals.

Given the results of previous research, the gene drive approach can even be used as prevention for some zoonotic diseases and, hence, possible future pandemics. For example, laboratory tests showed that the release of genetically modified mosquitoes can drastically reduce the number of malaria vectors. Nevertheless, potential environment and health implications, related to the release of GDO, remain unclear. Only a few potential applications have so far progressed to the research and development stage.

"The potential of GDOs for unlimited spread throughout wild populations, once released, and the apparently inexhaustible possibilities of multiple and rapid modifications of the genome in a vast variety of organisms, including higher organisms such as vertebrates, pose specific challenges for the application of adequate risk assessment methodologies," shares the lead researcher Mrs. Dolezel.

In the sense of genetic engineering being a fastly developing science, every novel feature must be taken into account, while preparing evaluations and guidance, and each of them provides extra challenges.

Today, the scientists present three key differences of gene drives compared to the classical GMO:

1. Introducing novel modifications to wild populations instead of "familiar" crop species, which is a major difference between "classic" GMOs and GDOs.

"The goal of gene drive applications is to introduce a permanent change in the ecosystem, either by introducing a phenotypic change or by drastically reducing or eradicating a local population or a species. This is a fundamental difference to GM crops for which each single generation of hybrid seed is genetically modified, released and removed from the environment after a relatively short period," shares Dolezel.

2. Intentional and potentially unlimited spread of synthetic genes in wild populations and natural ecosystems.

Gene flow of synthetic genes to wild organisms can have adverse ecological impact on the genetic diversity of the targeted population. It could change the weediness or invasiveness of certain plants, but also threaten with extinction the species in the wild.

Possibility for long-term risks to populations and ecosystems.

Key and unique features of GDOs are the potential long-term changes in populations and large-scale spread across generations.

In summary, the research team points out that, most of all, gene drive organisms must be handled extremely carefully, and that the environmental risks related to their release must be assessed under rigorous scrutiny. The standard requirements before the release of GDOs need to also include close post-release monitoring and risk management measures.

It is still hard to assess with certainty the potential risks and impact of gene drive applications on the environment, human and animal health. That's why highly important questions need to be addressed, and the key one is whether genetically driven organisms are to be deliberately released into the environment in the European Union. The High Level Group of the European Commission's Scientific Advice Mechanism highlights that within the current regulatory frameworks those risks may not be covered.

The research group recommends the institutions to evaluate whether the regulatory oversight of GMOs in the EU is accomodate to cover the novel risks and challenges posed by gene drive applications.

"The final decision to release GDOs into the environment will, however, not be a purely scientific question, but will need some form ofbroader stakeholder engagement and the commitment to specific protection goals for human health and the environment", concludes Dolezel.

Here is the original post:
The EU not ready for the release of Gene drive organisms into the environment - Science Codex

The science of changing the traits of plants in order to give rise to a desired trait is called plant breeding. CRISPR refers to clustered regularly interspaced short palindromic repeat and case 9 associated protein system is the plant breeding innovation that uses site-directed nucleases used to target and transform DNA with accuracy. It can be applied in a wide range of uses such as biological research, development od crops & animals and human health.

Increasing importance for sustainable crop production drives the growth of plant breeding and the CRISPR plants market. Besides this, a fall in the cost of genomic solutions also drives the growth. However, high costs involved in modern breeding techniques as compared to conventional breeding techniques restricts the growth. A uprurging investments from seed companies and supportive regulations for molecular breeding is expected to boost the growth of plant breeding and CRISPR plants market.

Get Sample Copy of this Report at:https://www.theinsightpartners.com/sample/TIPRE00010404/

Leading Plant Breeding and CRISPR Plants Market Players:

Plant Breeding and CRISPR Plants Marketto 2027research report conveys industrybusinesspatterns and the undertaking information, tolerating one to grasp clients and the stock driving gainfulness and yield development. The report highlights information on improvements and Plant Breeding and CRISPR Plants Markettrends, drivers, revenue and furthermore available. The market report pulls in the most peculiar bits of knowledge of this business additionally makes Plant Breeding and CRISPR Plants Market-forecast that is important out there.

The report contains imperative and pivotal details affecting the developments and growth of the market and also talks about the restricting factors that may restrain the Plant Breeding and CRISPR Plants Market growth during the forecast period. Segmentation of the market are examined specifically to provide knowledge for supplementary market investments. Segmentation of the market on the basis of Extract Type, Form and Application are elucidated in details portraying a descriptive structure of the market trends and restrictions affecting the Food Preservatives- Marketthrough the segments and sub-segments.

Purchase This Report at:https://www.theinsightpartners.com/buy/TIPRE00010404/

Reason to Buy:

Save and reduce time carrying Plant Breeding and CRISPR Plants research by identifying the growth, size, leading players and segments in the global Plant Breeding and CRISPR Plants Market Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in the Plant Breeding and CRISPR Plants Market, thereby allowing players to develop effective long term strategies. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

Website:https://www.theinsightpartners.com/

See more here:
Plant Breeding and CRISPR Plants Market Summary Comprises Key Regions, Growth and Segmentation Till 2027 - Jewish Life News

Something's been brewing in the health care sector, the second-largest group in the S&P 500. Since the start of the second quarter, the Health Care Select Sector SPDR (NYSE: XLV) is one of the top asset-gathering exchange traded funds.

The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), thanks to plenty of help from Gilead Sciences (NASDAQ: GILD), is up almost 14% over the past month. Much of the recent biotechnology ebullience is attributable to progress on the coronavirus treatment and vaccine front.

IBB is the largest biotechnology ETF by assets, but it's not the only one delivering impressive returns in recent weeks. Here's a trio of biotech ETFs that are knocking the cover off the ball.

Virtus LifeSci Biotech Clinical Trials ETF (BBC)

The Virtus LifeSci Biotech Clinical Trials ETF (NYSE: BBC) tracks the LifeSci Biotechnology Clinical Trials Index. That benchmark is a collection of companies with drugs and therapies in clinical trials, which means BBC is at the right place at the right time in the battle to quash coronavirus.

BBC's holdings are basically equally weighted, but that doesn't distract from the fact that Moderna (NASDAQ: MRNA) is the fund's top holding. Overall, BBC holds about 90 stocks, most of which dwell at the lower end of large-cap territory or are mid- or small-cap names.

In addition to Moderna, several other BBC components have coronavirus treatment exposure and roughly a dozen are credible takeover targets. That's enough to have BBC up nearly 27% over the past month.

ARK Genomic Revolution ETF (ARKG)

In the health care space, the ARK Genomic Revolution ETF (CBOE: ARKG) has been one of the best-performing funds for several years, trouncing traditional health care and biotechnology ETFs for several years, speaking to the capabilities of the fund's active managers.

ARKG typically holds 30 to 50 stocks and currently holds 34, several of which are coronavirus plays and that doesn't even begin to underscore the fund's virus detection exposure, which highlights ARKG's deep CRISPR exposure.

As government officials re-open the US, testing for the COVID-19 virus will be a critical step. A new CRISPR-based test called DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) could help speed the process along, ARK analyst Ali Aurman saidin a recent note.

ARKG is higher by nearly 32% over the past month.

Principal Healthcare Innovators Index ETF (BTEC)

The Principal Healthcare Innovators Index ETF (NASDAQ: BTEC) is a departure from the other funds mentioned here because it's not drug/therapy-centric. Rather, BTEC tilts more toward medical device, equipment and life sciences firms.

The fund invests in companies that are leading the charge toward innovative solutions, rather than spending money on marketing and distribution, according to Principal.

BTEC's nearly 210 holdings are considered research and development-intensive companies and the fund's methodology screens out companies with negative or inconsistent earnings. The fund is higher by almost 25% over the past month.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more from the original source:
3 Biotech ETFs Up 10% Or More Over The Last Month - Benzinga

-Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies-

-Enrollment ongoing in clinical trial of CTX110, targeting CD19+ malignancies-

-Began treating patients in clinical trial of CTX120, targeting B-cell maturation antigen (BCMA)-

-IND and CTA approved for CTX130, wholly-owned allogeneic CAR-T cell therapy targeting CD70-

-Received $25 million milestone payment from DMD/DM1 collaboration with Vertex in April 2020-

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2020.

"We made substantial progress in the last quarter despite the challenges posed by COVID-19. We are now progressing five cell therapy clinical trials in parallel targeting hemoglobinopathies and various cancers," said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. "Our CTX001 and CTX110 programs continue to enroll patients, and we expect to report data for these programs this year. We are pleased to have begun treating patients in our CTX120 trial for the treatment of relapsed or refractory multiple myeloma and we expect to begin treating patients in our CTX130 trial in renal cell carcinoma and T-cell and B-cell hematologic malignancies in the second half of this year. Despite these unprecedented times, we continue to execute on our programs and we remain focused on our commitment to patients and their families."

Recent Highlights and Outlook

Title: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models (abstract #1046)Session Title: Gene Targeting and Gene CorrectionDate and Time: Thursday, May 14, 2020; 5:30 PM - 6:30 PM

Title: Multiplexing of Up to 10 Gene Edits Using CRISPR/Cas9 to Generate CAR-T Cells with Improved Function (abstract #1151)Session Title: Cancer - Immunotherapy, Cancer VaccinesDate and Time: Thursday, May 14, 2020; 5:30 PM - 6:30 PM

First Quarter 2020 Financial Results

About CTX001CTX001 is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth and is then replaced by the adult form of hemoglobin. The elevation of HbF by CTX001 has the potential to alleviate transfusion requirements for TDT patients and painful and debilitating sickle crises for SCD patients.

CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics and Vertex.

About CTX110CTX110 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19, or CD19, for the treatment of CD19+ malignancies. A wholly-owned asset of CRISPR Therapeutics, CTX110 is being investigated in a clinical trial designed to assess the safety and efficacy of CTX110 for the treatment of relapsed or refractory B-cell malignancies. The multi-center, open-label clinical trial is designed to enroll up to 95 patients and investigate several dose levels of CTX110.

About CTX120CTX120 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting B-cell maturation antigen, or BCMA. A wholly-owned asset of CRISPR Therapeutics, CTX120 is being investigated in a clinical trial designed to assess the safety and efficacy of CTX120 for the treatment of relapsed or refractory multiple myeloma. The multi-center, open-label clinical trial is designed to enroll up to 80 patients and investigate several dose levels of CTX120.

About CTX130CTX130 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. A wholly-owned asset ofCRISPR Therapeutics, CTX130 is being developed for the treatment of both solid tumors, such as renal cell carcinoma, and T-cell and B-cell hematologic malignancies.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) potential impacts due to the coronavirus pandemic; (ii) the safety, efficacy and clinical progress of CRISPR Therapeutics' various clinical programs including CTX001, CTX110, CTX120 and CTX130; (iii) the status of clinical trials (including, without limitation, the timing of filing of clinical trial applications and INDs, any approvals thereof, the timing of commencement of clinical trials and the expected timing of data releases), development timelines and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics and its collaborators; (iv) the number of patients that will be evaluated, the anticipated date by which enrollment will be completed and the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; (v) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties as well as the status and potential outcome of proceedings involving any such intellectual property; (vi) the sufficiency of CRISPR Therapeutics' cash resources; (vii) the expected benefits of CRISPR Therapeutics' collaborations; and (viii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects" and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential impacts due to the coronavirus pandemic such as (x) delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; (y) the timing and progress of clinical trials, preclinical studies and other research and development activities; and (z) the overall impact of the coronavirus pandemic on its business, financial condition and results of operations; the potential for initial and preliminary data from any clinical trial (including CTX001, CTX110, CTX120 and CTX130) not to be indicative of final trial results; the risk that the initial data from a limited number of patients (as is the case with CTX001 at this time) may not be indicative of results from the full planned study population; the outcomes for each CRISPR Therapeutics' planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics' internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics' product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics' product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics' technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics' most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:Susan Kimsusan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR617-337-4167 reides@wcgworld.com

Read more:
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results - Benzinga

The first manned experiments were carried out in China with CRISPR gene editing technology. In a study with cancer patients, the treatment was shown to be safe and permanent.

Scientists and researchers continue to work on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a gene editing technology. The first manned experiments with this gene editing technology were completed.

In these first experiments using CRISPR technology, quite promising developments took place. In the experiment, it was revealed by the researchers that the treatment was safe and permanent.

Cancer treatment with CRISPR:A team led by You Lu from West China Hospital applied CRISPR to take the immune cells of people with lung cancer to neutralize a gene called PD-1. The PD-1 protein usually sends signals to the immune cells to hold the attacks from the bodys own tissues, but the active PD-1 also extends the gates to spread the cancer.

The team then injected each participant with a modified version of their own immune cells. The participants experienced quite mild side effects. In addition, potentially dangerous gene mutations from gene regulation, the greatest fear of researchers, were very limited.

These cells, regulated by CRISPR, remained in the blood for at least four weeks, and this also showed that the effects of the strategy could be permanent, but this experiment in China was conducted with only 12 people with cancer. The authors of the article called for more comprehensive studies with newer gene editing systems. Many CRISPR based experiments guided this study, some of which have already been reported.

Read this article:
The Treatments Carried Out With CRISPR Have Been Proved To Be Safe For People - Somag News

BAILARD, INC. bought a fresh place in CRISPR Therapeutics AG (NASDAQ:CRSP). The institutional investor bought 53.0 thousand shares of the stock in a transaction took place on 3/31/2020. In another most recent transaction, which held on 3/31/2020, FRONTIER CAPITAL MANAGEMENT CO. bought approximately 38.5 thousand shares of CRISPR Therapeutics AG In a separate transaction which took place on 3/31/2020, the institutional investor, IMA WEALTH, INC. bought 38.3 thousand shares of the companys stock. The total Institutional investors and hedge funds own 54.30% of the companys stock.

In the most recent purchasing and selling session, CRISPR Therapeutics AG (CRSP)s share price decreased by -0.99 percent to ratify at $52.00. A sum of 1315673 shares traded at recent session and its average exchanging volume remained at 993.63K shares. The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of a stock. CRISPR Therapeutics AG (CRSP) shares are taking a pay cut of -29.73% from the high point of 52 weeks and flying high of 60.99% from the low figure of 52 weeks.

CRISPR Therapeutics AG (CRSP) shares reached a high of $53.615 and dropped to a low of $49.33 until finishing in the latest session at $53.25. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Currently at 3.32 is the 14-day ATR for CRISPR Therapeutics AG (CRSP). The highest level of 52-weeks price has $74.00 and $32.30 for 52 weeks lowest level. After the recent changes in the price, the firm captured the enterprise value of $2.36B, with the price to earnings ratio of 53.55. The liquidity ratios which the firm has won as a quick ratio of 17.30, a current ratio of 17.30 and a debt-to-equity ratio of 0.00.

Having a look at past record, were going to look at various forwards or backwards shifting developments regarding CRSP. The firms shares fell -0.76 percent in the past five business days and grew 17.41 percent in the past thirty business days. In the previous quarter, the stock fell -4.06 percent at some point. The output of the stock increased 15.94 percent within the six-month closing period, while general annual output gained 29.39 percent. The companys performance is now negative at -14.62% from the beginning of the calendar year.

According to WSJ, CRISPR Therapeutics AG (CRSP) obtained an estimated Overweight proposal from the 17 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 2 equity research analysts rated the shares with a selling strategy, 4 gave a hold approach, 11 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. The average price goal of one year between several banks and credit unions that last year discussed the stock is $74.25.

CMS Energy Corporation (CMS) shares on Wednesdays trading session, dropped -3.29 percent to see the stock exchange hands at $57.26 per unit. Lets a quick look at companys past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end. The company posted a value of $2.28 as earning-per-share over the last full year, while a chance, will post $2.85 for the coming year. The current EPS Growth rate for the company during the year is 3.00% and predicted to reach at 8.21% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was 5.60% for the past five years and the scenario is totally different as the current prediction is 7.30% for the next five year.

The last trading period has seen CMS Energy Corporation (CMS) move -17.22% and 24.40% from the stocks 52-week high and 52-week low prices respectively. The daily trading volume for CMS Energy Corporation (NYSE:CMS) over the last session is 2.64 million shares. CMS has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -5.36% compared to the previous one.

Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings. As a return on equity, CMS Energy Corporation (NYSE:CMS) produces 13.80%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for CMSs scenario is at 5.80%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over a duration of time. CMS Energy Corporation (CMS) generated 2.60% ROA for the trading twelve-month.

Volatility is just a proportion of the anticipated day by day value extendthe range where an informal investor works. Greater instability implies more noteworthy benefit or misfortune. After an ongoing check, CMS Energy Corporation (CMS) stock is found to be 3.27% volatile for the week, while 4.28% volatility is recorded for the month. The outstanding shares have been calculated 287.81M. Based on a recent bid, its distance from 20 days simple moving average is -3.57%, and its distance from 50 days simple moving average is -6.24% while it has a distance of -7.97% from the 200 days simple moving average.

The Williams Percent Range or Williams %R is a well-known specialized pointer made by Larry Williams to help recognize overbought and oversold circumstances. CMS Energy Corporation (NYSE:CMS)s Williams Percent Range or Williams %R at the time of writing to be seated at 97.98% for 9-Day. It is also calculated for different time spans. Currently for this organization, Williams %R is stood at 98.20% for 14-Day, 67.39% for 20-Day, 51.47% for 50-Day and to be seated 51.47% for 100-Day. Relative Strength Index, or RSI(14), which is a technical analysis gauge, also used to measure momentum on a scale of zero to 100 for overbought and oversold. In the case of CMS Energy Corporation, the RSI reading has hit 45.34 for 14-Day.

See the article here:
Solid Income Opportunity With CRISPR Therapeutics AG (CRSP) and CMS Energy Corporation (CMS) - BOV News

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2020 financial results and operational highlights in a conference call on May 7, 2020 at 8 a.m. ET.

To join the call:

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the companys website at http://www.intelliatx.com, beginning on May 7, 2020 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investor Contact:Lina LiAssociate Director, Investor Relations+1 857-706-1612lina.li@intelliatx.com

Media Contact:Jennifer Mound SmoterSenior Vice President, External Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Continued here:
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates - Yahoo Finance

ETF Trends CEO Tom Lydon discussed the ARK Genomic Revolution Multi-Sector Fund (ARKG)on this weeks ETF of the Week podcast with Chuck Jaffe on the MoneyLife Show.

The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from the team at ARK Invest that tries to pick the companies best positioned to profit from advancements in energy, automation, manufacturing, materials, and transportation.

ARKG is an outperforming biotech ETF. As far as 1-month performances: ARKG is +43.7% versus the benchmark Nasdaq Biotechnology Index at +26.4%. Year-to-date, ARKG is +15.7% versus Nasdaq Biotechnology Index at +2.4%.

Concerning today, there is short-term support from the hope of a viable COVID-19 drug. For example, Pluristem (PSTI) surged on news that it had treated seven severely ill patients with COVID-19 in Israel with its allogeneic placental expanded (PLX) cells, with a survival rate of 100%, and It has treated at least one patient in the United States as well.

ARKG capitalizes on innovative, specialized drugs that are being developed by many overlooked names. Iovance (IOVA) climbed after it announced it would present data on its Phase 1 Study Combining Tumor-Infiltrating Lymphocytes (TIL) and Nivolumab in Non-Small Cell Lung Cancer. Compugen (CGEN) jumped on news that the company will present potentially positive updates on its ongoing Phase 1 immuno-oncology clinical trial evaluating COM701.

Looking at the long-term outlook, ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to understand better how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, pharmaceuticals, and improving our quality of life.

The convergence of Artificial Intelligence (AI), Next Generation DNA Sequencing (NGS) and CRISPR gene-editing has the potential to boost the efficiency of drug development radically. Breakthroughs in genomic science can present new treatments to help patients recover from what were once believed to be incurable afflictions.

For the record, the global genomics market was worth $851.96 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 14.71% and reach $1.5 billion by 2023. Rising government funds for research on genomics drives the growth of the single-cell genomics market. The government funding focuses on efforts to resolve the complexity of the human genome, the genomic basis of human health and disease, and ensure that genomics is used safely to enhance patient care and benefit society through government, public and private institutions.

Related:ETF of the Week: ProShares Long Online/Short Stores ETF (CLIX)

Scientists have identified more than 50,000 genetic diseases caused by single-gene mutations, many of which are likely to be treated through genomic approaches, including several methods that have already begun to receive FDA approval. Looking ahead, CRISPR-based innovations to accelerate given the technologys ease of use, cost-efficacy, a growing body of research surrounding its safety and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

Bolstering the case for ARKG over the long-term is the importance of genomics in an array of clinical trials. Drug development companies are making clinical trials more efficient by using NGS to find and enroll patients likely to respond. Half of the clinical trials and 80% of oncology trials now collect genetic information. ARK believes that clinical trials using genetic diagnostics will result in fewer failed drugs and will increase capital efficiency.

Go here to read the rest:
ETF of the Week: ARK Genomic Revolution Multi-Sector Fund (ARKG) - ETF Trends

WOBURN, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHISs Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10s submission along with the USDA-APHIS BRS response is posted on theUSDAs website.

In January 2020, Yield10 submitted an Am I Regulated? letter to the BRS, requesting confirmation of the regulatory status for Camelina plant lines containing the Companys novel, CRISPR genome-edited C3007 trait. The positive USDA-APHIS response came in the form of a published letter indicating that the plant lines do not meet the definition of a regulated article under 7 CFR Part 340.

This clarification of the regulatory status under USDA-APHIS guidelines accelerates the path for Yield10 to conduct field trials of the CRISPR genome-edited C3007 plants in the United States in the 2020 growing season. The plant lines may still be subject to regulation by the U.S. Environmental Protection Agency (EPA) or the U.S. Food and Drug Administration (FDA).

Receiving a positive response from USDA-APHIS for our CRISPR genome-edited C3007 lines is a critical milestone within our development program and facilitates the transition of lines with this trait to field testing this year, said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. Initial studies with C3007 have demonstrated potential for increased oil content, and the next step of testing this trait under field conditions will help us to characterize its performance and role in boosting oil content in Camelina and other oilseed crops.

The ability to increase oil content in specialty oilseed crops like Camelina has the potential to make a significant impact in the supply of omega fatty acid containing oils, to human nutrition and aquaculture feed markets. Further, the continued analysis of C3007 and its role as a key regulator of oil content in Camelina may also enable this trait to be used to increase production of edible oils in other major oilseed crops such as soybean and canola.

Once again, we appreciate both the speed and the transparency in which USDA-APHIS reviewed our letter and the data we provided, which has enabled us to plan our first field trials with this trait in 2020, said Dr. Oliver Peoples, Chief Executive Officer of Yield10 Bioscience. It is this sound, science-based regulatory framework that we believe is so important to the successful development and commercialization of new technologies for agriculture to increase crop performance, as well as other efforts to address sustainable global food security.

Yield10 licensed C3007 from the University of Missouri (MU) in 2018. The protein encoded by C3007, also known as BADC, is a novel regulator of the enzyme acetyl-CoA carboxylase (ACCase), the key enzyme for producing fatty acids for oil biosynthesis. In pilot studies conducted by MU researchers, reducing activity of the protein encoded by C3007 resulted in significantly increased oil content in seeds.Yield10 researchers have successfully used CRISPR to inactivate a number of the C3007 gene copies in Camelina and have seen clear evidence of increased oil content in some lines in laboratory studies. The use of CRISPR to deploy the trait may enable an expedited timeline for development and commercialization within the U.S. market.

The CRISPR genome-edited C3007 trait could deliver significant economic value by changing the value equation for the commercialization of identity preserved, specialty oilseed crops where the key value-driver is oil content with improved nutritional profiles for human consumption or for aquaculture feed or industrial markets. These traits may also be used to increase production of edible oils in major oilseed crops such as soybean and canola.

AboutYield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations to improve crop yields and enhance sustainable global food security. The Company utilizes its proprietary GRAIN (Gene Ranking Artificial Intelligence Network) gene discovery platform to identify gene targets to improve yield performance and value in major commercial food and feed crops. Yield10 uses its Camelina oilseed platform to rapidly evaluate and field test new trait leads enabling the translation of promising new traits into the major commercial crops. As a path toward commercialization, Yield10 is pursuing a partnering approach with agricultural companies to drive new traits into development in crops such as canola, soybean and corn. The Company is also developing Camelina as a platform crop for producing nutritional oils and specialty products such as PHA biomaterials for use in water treatment applications. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visitwww.yield10bio.com, or follow the Company onTwitter,FacebookandLinkedIn.

(YTEN-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements regarding the Company's ability to conduct field testing of C3007 in Camelina plant lines in 2020, the possibility that testing this trait under field conditions will help us to characterize the performance of the trait and its role in boosting oil content in Camelina and other oilseed crops, the ability of C3007 to increase oil content in Camelina and other oilseed crops, the potential to make a significant impact in the supply of omega fatty acid containing oils to human nutrition and aquaculture feed markets, the potential for the trait to be used to increase production of edible oils in other major oilseed crops such as soybean and canola, the potential for an expedited timeline for development and commercialization within the U.S. market, the possibility for the trait to deliver economic value in other areas, and the possibility of translating promising new traits into the major commercial crops, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

Contacts:Yield10 Bioscience:Lynne H. Brum, (617) 682-4693,LBrum@yield10bio.com

Investor Relations Contact:Bret Shapiro, (561) 479-8566,brets@coreir.comManaging Director, CORE IR

Media Inquiries:Eric Fischgrund,eric@fischtankpr.comFischTank Marketing and PR

Read this article:
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way...

Wall Street expects a year-over-year decline in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports results for the quarter ended March 2020. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This company is expected to post quarterly loss of $1.09 per share in its upcoming report, which represents a year-over-year change of -17.2%.

Revenues are expected to be $6.35 million, up 1824.2% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CRISPR Therapeutics AG?

For CRISPR Therapeutics AG, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

Story continues

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that CRISPR Therapeutics AG will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CRISPR Therapeutics AG would post earnings of $0.04 per share when it actually produced earnings of $0.51, delivering a surprise of +1,175%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CRISPR Therapeutics AG doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

More here:
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

If we take the advice of health experts, we wont be attempting a return to normal life in the US until we get better at identifying people infected with the novel coronavirus. That need is driving researchers across the nation to look for ways to expand our toolbox of testing options. And now a new test, developed using CRISPR gene editing technology, has been added to the mix.

About 5.4 million tests have been done in the US, according to the COVID Tracking Project, in a population of 328.2 million. That might sound like enough to keep ahead of an infectious disease that has only killed in five figures, but such an assumption grossly oversimplifies the situation.

Controlling the pandemic in the US is going to require a daunting number of diagnostic tests not just for the sick, but to verify when theyre better (two tests 24 hours apart for hospital discharge), in contact tracing to limit spread, and in the many individuals whove been infected but have few or no symptoms.

In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies, write Matthew P. Cheng, MDCM. McGill University Health Centre and colleagues in a recent article in Annals of Internal Medicine. The US isnt on that list and has been struggling to catch up.

Simply put, we need faster, cheaper and more accurate tests than what we currently have. If they can be administered at home or in informal settings, all the better. Among the potential solutions for this challenge are efforts to turn everyones favorite gene editing tool, CRISPR, against the coronavirus. If successful, we could see a shift in access to tests. Imagine being able to use a nasal swab that delivers a yes or no verdict on coronavirus infection in under 40 minutes essentially like a home pregnancy test.

A CRISPR-based diagnostic is in the sights of researchers at the University of California, San Francisco Medical School and Mammoth Biosciences, which recently revealed plans for an inexpensive, compact test.

I can run it now myself at home, said Dr. Charles Chiu, professor of laboratory medicine at UCSF and co-lead developer of the new test, in an interview with NPR. Still, he acknowledged the test, which is being submitted for FDA approval, isnt yet simple enough for the average person to operate. He expressed confidence that a home-based test for nonexperts is within reach.

What we really want to develop is something like a handheld, pocket-sized device using disposable cartridges, he told NPR.

So, where would such CRISPR-based tests fit within the universe of coronavirus diagnostics? Theres little reason to think they would replace other testing options. Rather, think of them as offering another option for hospitals, clinics, doctors, and even consumers. That said, lets take a look at where we are in testing.

Diagnostic tests use a version of the polymerase chain reaction (real-time reverse transcriptase PCR) to amplify pieces of the RNA genome of SARS-CoV-2, the virus behind COVID-19. Dr. Deborah Birx, Coronavirus Response Coordinator, suggested that antigen-based tests be added to increase the supply, but these detect protein antigens on the viral surface, not the genetic material, and may be less likely to indicate infectious virus. For influenza diagnostic testing antigen tests are less accurate than the PCR-based tests.

PCR is simple in concept, but not always easy to carry out. It requires raising and lowering the temperature repeatedly as nucleic acid sequences are copied. Reagents may run out, and it requires specialized equipment. A PCR-based test that could diagnose infection in a few hours often takes more than a day because the sample must be sent to a lab.

False negatives can occur if viral RNA in a sample degrades during shipping, or if not enough collects on the swab. If either happens and a patient worsens, another test is required. But if the virus descends into the lungs, not enough may remain in the throat for a test to pick it up, even though the patient is actually sicker.

And so some people with obvious symptoms of COVID-19 must have two or three tests before a result is positive.

But PCR-based tests are what we have. Regulations shifted into emergency mode to bolster supplies.

On February 4, the Food and Drug Administration (FDA) greenlighted the Emergency Use Authorization (EUA) of the Center for Disease Control and Preventions (CDC) PCR test, making it available to to state and local public health labs and the Department of Defense. The EUA enables rapid roll-out of a still-experimental test. Even though PCR has been used in clinical diagnostics for decades, the virus is new and therefore so is the test.

A PCR-based diagnostic for COVID-19 amplifies RNA sequences unique to the novel virus, as well as gene parts common to other coronaviruses and a control sequence (encoding an enzyme, RNase), to make sure the test is working.

But at the end of January, bits of viral RNA in the CDC facility tainted some of the first test kits, so that they could yield false positive results, delaying their use.

On February 28, FDA took further action, announcing that clinically-licensed labs can use in-house developed tests while awaiting the EUA. These labs are CLIA-compliant,which means that they satisfy the standards of the Clinical Laboratory Improvement Amendments set by the federal government.

So places like Meridian Health, the Cleveland Clinic, Stanford Medicine, and many others began to do part of the PCR work-up, so that they didnt have to outsource samples. It was a little like people addicted to going to Starbucks learning how to make their own brew at home maintaining standards but taking on more of the task. (In fact, a study was just published on how to make the healthiest at-home brew.)

Michelle N. Gong, MD, Chief of Critical Care Medicine at Montefiore Medical Center in the Bronx, said on a JAMA Network webinaron March 23 that bringing the testing in-house immediately escalated testing.

We started with sending samples to the Department of Health, but it became increasingly clear that it was not going to be adequate. It took days. Our hospitals epidemiologist worked to bring testing onsite and that has changed the game. The ability to test onsite and turn it around fast made it much more efficient to get patients what they need.

The FDAs list of diagnostics granted EUA status continues to grow. The last time I checked it had 62 entries.

On March 27, the EUA granted Abbott Labs use of a test that they had under development that detects two viral genes (N and RdRp), one of them different from the CDCs recipe. According to the company, the test can deliver positive results in 5 minutes and negative results in 13 minutes.

The Abbott test runs on an existing platform, ID NOW, and uses a gene amplification technology that doesnt require the temperature shifts of PCR. The test is done in a lightweight box about the size of a toaster thats already used in doctors offices, urgent care facilities, and emergency departments to rapidly diagnose influenza, strep, and respiratory syncytial virus.

But the companys initial forecast of providing 50,000 tests a day, starting soon, may need to await further validation. A researcher at the Cleveland Clinic, Gary Procop, MD, tested five products on 239 patient samples known to be positive for COVID-19. Abbotts test missed 15 percent.

The World Health Organization (WHO)also provided many tests early on and continues to do so.

On April 21, FDA re-deployed the Emergency Use Authorization of LabCorpsPCR-based test for use in a home-kit that the company provides. Its being rolled out for health care workers first; consumer tests may follow in a few weeks.

Another way to boost test kit supplies is to harness the gene editing tool CRISPR. It may be faster and simpler than PCR.

The team from Mammoth Biosciences and UCSF reported on CRISPRCas12-based detection of SARS-CoV-2 in April 16s Nature Biotechnology. Company co-founder is Jennifer Doudna, PhD, co-inventor of CRISPR.

Mammoths visual readout strip works at the bedside, is fast, and in trials so far, picks up 100% of negatives and 95% of positives although much more extensive evaluation is needed. The report considers findings in 36 patients with COVID-19 and 42 people with other respiratory illnesses.

On February 15 Mammoth unveiled the protocol for their point of care test in a white paper that describes it as useful in areas at greatest risk of transmitting SARS-CoV-2 infection, including airports, emergency departments, and local community hospitals, particularly in low-resource countries.

We need faster, more accessible and scalable diagnostics. The point-of-care testing space is ripe for disruption and CRISPR diagnostics have the potential to bring reliable testing to the most vulnerable environments, said Mammoths Chief Technology Officer Janice Chen, PhD.

The test uses the companys DETECTR technology; that stands for DNA Endonuclease-Targeted CRISPR Trans Reporter. The platform had already been in the works for human papillomavirus, described in a April 27, 2018 report in Science.

The company started revamping its system for the novel coronavirus as soon as cases were reported from Wuhan, and within two weeks was testing it on the first patient samples. Because CRISPR can be programmed to detect any DNA or RNA sequence, we reconfigured our DETECTR platform within days to detect the SARS-CoV-2 virus from one of the first confirmed cases in the U.S., said Dr. Chen.

The system collapses the two steps of PCR-based tests into one: copying viral RNA into DNA and amplifying it fast, without temperature shifts. The test snips off a reporter molecule that generates the stain on the paper read-out strip, and uses the Cas12enzyme, which makes more precise cuts than conventional Cas9.

The test zeroes in on three gene pieces:

It picks up 70 to 300 DNA pieces of genetic material per microliter of fluid from a nose or throat swab. A microliter is one-millionth of a liter.

SHERLOCK, for Specific High Sensitivity Enzymatic Reporter Unlocking, is a testing platform coming from work on Zika virus disease and Dengue fever published in 2018 in Science. Sherlock Biosciences provides the test and Cepheid.com provides their GeneXpert Systems cartridge device. The approach licenses work from the Broad Institute, home of another CRISPR founder, Feng Zhang, PhD.

The system can identify any genetic target, and therefore any infectious disease. The test for COVID-19 may reach the market as a dip stick, paper strip, or even an electrochemical readout that can be read with a mobile phone, according to company information.

The system zeroes in on genome pieces unique to SARS-CoV-2 that encode the spike (S) protein and apolyprotein that commandeers the host cell. (My blog post from the start of the pandemic, COVID-19 Vaccine Will Close in on the Spikes, explains the genetic make-up of the virus.)

It uses powerful Cas12 and Cas13 enzymes and can reportedly detect down to the single molecule level. Its fast, accurate, and works directly on body fluids. And with 23,000 GeneXpert Systems already at health care facilities, popping in a COVID test may be the best idea yet.

To biologists and many others it was clear from the start that fighting this pandemic would require far more testing than for just the people who show up at health care facilities with symptoms. An epidemic is a population phenomenon that must be addressed at that level. It is comforting to know that regulations were in place to allow implementation of variations on the testing theme, and that the companies that have long expected a viral pandemic are collaborating to rapidly adapt existing tests, tools and technologies to put the pandemic of 2020 behind us.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Read this article:
'At home' coronavirus test? How CRISPR could change the way we search for COVID-19 - Genetic Literacy Project

27 April 2020

Genome-edited human stem cells from diabetic patientshavebeen shown to successfully reverse diabetes in mice.

Researchers at Washington University School of Medicine in St Louis, Missouri, used CRISPR/Cas9 to correct a genetic defect in human stem cells and then converted them into cells capable of producing insulin. When these edited insulin-producing cells were implanted into diabetic mice, they were able to effectively control blood sugar levels for six months.

'We're excited about the fact that we were able to combine these two technologies - growing beta cells from induced pluripotent stemcells and using CRISPR to correct genetic defects,' said corresponding author Dr Jeffrey Millman. 'This is the first time CRISPR has been used to fix a patient's diabetes-causing genetic defect and successfully reverse diabetes.'

The human cells used were from a patient with a rare genetic type of diabetes called Wolfram syndrome, which develops during childhood and typically requires affected patients to inject insulin multiple times each day.

'For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping-stone toward applying gene therapy to a broader population of patients with diabetes,' said Dr Millman.

The same team previously developed a new technique to more efficiently convert human stem cells into insulin-producing cells, allowing them to 'functionally cure' diabetes in mice for the first time (see BioNews1037). In the current study, they went one step further, adding the genome editing step to make cells from a diabetic personproduce insulin.

'We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation,' said Dr Fumihiko Urano, who co-led the study. 'In fact, we found that corrected beta cells were indistinguishable from beta cells made from the stem cells of healthy people without diabetes,' added Dr Millman.

'It's also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration' said Dr Urano.

The study was published in the journal Science Translational Medicine.

View original post here:
Diabetes reversed in mice using CRISPR and stem cell therapy - BioNews

There is widespread agreement that the only way to safely reopen the economy is through a massive increase in testing. The US needs to test millions of people per day to effectively track and then contain the covid-19 pandemic.

This is a tall order. The country tested only around 210,000 people per day last week, and the pace is not increasing fast enough to get to millions quickly.

The urgency to do better is overwhelmingly bipartisan, with the most recent legislation adding $25 billion for testing a few days ago. Fears are growing, however, that testing might not scale in time to make a difference. As Senators Lamar Alexander and Roy Blunt wrote last week, We have been talking with experts across the government and the private sector to find anyone who believes that current technology can produce the tens of millions of tests necessary to put this virus behind us. Unfortunately, we have yet to find anyone to do so.

We believe that it can be done. The scientific community has the technological capabilities today to test everyone who needs it and enable people to come back to work safely.

To be clearthe senators are right that simply scaling up current practices for covid testing is insufficient. However, with a bit of innovation, the US can meet the need without inventing entirely new technologies. The necessary scale can be achieved by deploying the fruits of the last decade of innovation in biology, including the dizzying advances in DNA sequencing, genetic engineering, industrial automation, and advanced computation.

We speak from experience. We have worked with and helped engender many of these technologies across academia and industry. Scaling them for widespread testing will require investment, infrastructure, and determination, but nothing technologically or logistically infeasible.

Tests for mass screening may have different requirements and characteristics from the tests run in clinical labs today that are approved by the Food and Drug Administration. So what might a solution look like?

It must be scalable, meaning tens or hundreds of thousands of tests per day per facility, or at-home tests. It must be sensitive to early stages of infection, detecting the actual virus rather than immunity to it. And it must be less bound by health insurance and regulatory constraints, to allow fast and broad testing, contact tracing, and isolation. These differences do not mean lower standards. In fact, screening at this scale will require stringent requirements for safety, accuracy, and reliability.

The life sciences community is rising to the challenge. We are repurposing our labs to advance new centralized and at-home methods that solve the bottlenecks preventing testing from reaching global scale. This community is moving fast, with shared purpose and a commitment to open collaboration. As a result of these efforts, several promising avenues are emerging.

Some rely on DNA sequencing tools that have improved a million-fold since the completion of the Human Genome Project nearly 20 years ago. Not only can these tools now read trillions of base pairs of human DNA every day, but they can be readily repurposed to test for the presence of coronavirus at mass scale, using instruments that already exist across the country. Some methods, such as SHERLOCK and DETECTR, harness CRISPR DNA and RNA recognition tools to enable rapid, distributed testing in doctors offices and at other sites. Other efforts are removing critical bottlenecks, such as sample purification, to make the existing approaches more scalable.

There are additional possibilities, and the US needs to place bets on several of them at the same time. Some of those bets might fail, but the severity of the moment requires that we try. Chances are, we will need more than one of them.

As important as the diagnostic technology itself is the need to fuel innovation at all stages of the testing process, including sample collection, regulation, logistics, manufacturing, distribution, scale-up, data infrastructure, and billing. These are solvable problems. The solutions may sometimes differ from current clinical testing conventions, but these are not conventional times.

Maybe cotton swabs or saliva can be used for collection rather than traditional nasopharyngeal swabs, which are in critically short supply. Maybe mass screening tests dont have to have the tested persons name and date on every collection tube but could instead include a bar code that you snap a picture of with your phone. Maybe these tests can be self-administered at home or work rather than conducted by trained professionals in clinical settings. Maybe samples from low-risk, asymptomatic people can be pooled together for initial testing and further screened only in the event of a positive result. This would allow many more samples to be analyzed at once.

State or federal regulatory agencies could make these adjustments to conventional practices more easily if they were willing to treat mass screening for bringing people back to work differently from the testing used in clinical settings. In addition, mass screening efforts will require unconventional partnerships with private companies, nonprofits, universities, and government agencies to support the logistics, collection, manufacturing, scale-up, and data infrastructure to make such a system possible. All this can be done, and some of it is already starting to be donebut we must not lose hope.

The United States capabilities in the life sciences and information technology are unmatched in the world. The time is now to rapidly build a massively scaled screening program that will save lives while allowing us to reopen our economy and keep it open. This can be done, but it will require urgency and determination to make multiple, simultaneous bets on infrastructure, regulation, and technology, as well as collaboration to put it all together.

We have united before to face far greater challenges as a nation, and we can do so again.

Sri Kosuri is cofounder and CEO of Octant and an associate professor in the Department of Chemistry and Biochemistry at UCLA. Feng Zhang is the James and Patricia Poitras Professor of Neuroscience at MITs McGovern Institute, a core member of the Broad Institute, a Howard Hughes Medical Institute Investigator, and cofounder of Sherlock Biosciences. Jason Kelly is cofounder and CEO of Ginkgo Bioworks. Jay Shendure is a Howard Hughes Medical Institute Investigator at the University of Washington School of Medicine and scientific director of the Brotman Baty Institute.

Originally posted here:
The US already has the technology to test millions of people a day - MIT Technology Review

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is already trouncing basic biotechnology and healthcare ETFs and historical data suggest that even if a recession lingers, ARKG could prove durable.

SVB Leerink analyst Geoffrey Porges recently pointed out in a note to clients that biotechnology and pharmaceutical benchmarks topped the broader market during the 2001 recession, the global financial crisis, and during the current economic malaise.

On average, the biotechnology Indexes declined -1% during the three economic downturns, compared with the pharmaceutical indexs -10% and the S&P 500 indexs -20%, reports Josh Nathan-Kazis for Barrons.

ARKG is a credible long-term investment. Over the past three years, the fund is up nearly 105% or more than triple the returns of the Nasdaq Biotechnology Index over the same span. During that period, the ARK fund more than doubled the aforementioned S&P 500 Health Care Index

Some predictable catalysts explain ARKGs potential durability in a recession.

People need their medicine, even in a recession. Porges cited published papers showing that pharmaceutical sales volume stayed steady in the U.S. during the 2008-09 recession, according to Barrons.

The ARK Investment teams process tries to focus on innovation and takes advantage of market inefficiencies. For example, the market easily can be distracted by short-term price movements, losing focus on the long-term effect of disruptive technologies.

Genomic sequencing is changing the way biological information is collected, processed, and applied. ARKG is focused on the disruptive innovations that are increasing precision, restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life, according to ARK Invest.

The ARK Investment teams process tries to focus on innovation and takes advantage of market inefficiencies. For example, the market easily can be distracted by short-term price movements, losing focus on the long-term effect of disruptive technologies.

Related:Big Growth Awaits a Golden Genomics ETF

Our analysis of historical recessions suggested that the biotech and pharma indices (and stocks) significantly outperformed the broad market (S&P 500), despite the greater P/E multiple compressions in the healthcare indices, writes SVBs Porges.

ARKG also offers some of the best CRISPR exposure of any ETF on the market. CRISPR-based innovations to accelerate given the technologys ease of use, cost-efficacy, a growing body of research surrounding its safety and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

See the original post here:
This Biotechnology ETF Could Be the Place to Be in a Recession - ETF Trends

The Global CRISPR Technology Market report vastly covers profiles of the companies who have made it big in this particular field along with their sales data and other data. It also suggests the business models, innovations, growth and every information about the big manufacturers that will be present the future market estimates. The Global CRISPR Technology Market report offers a holistic view of the industry along with the several factors which are driving the Global CRISPR Technology Market. It also shows the possible restraining factors which may hinder the growth of the Global CRISPR Technology Market. The Global CRISPR Technology Market study offers a complete analysis of the market size, segmentation, and market share.

This study covers following key players:

Thermo Fisher ScientificMerck KGaAGenScriptIntegrated DNA Technologies (IDT)Horizon Discovery GroupAgilent TechnologiesCellecta, Inc.GeneCopoeia, Inc.New England BiolabsOrigene Technologies, Inc.Synthego CorporationToolgen, Inc.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4459840

The CRISPR Technology Market study is major compilation of significant information with respect to the competitor details of this market. The data offered in this report is gathered based on the deep market understanding on latest industry news, trends, as well as opportunities. This study offers a separate analysis of the major trends in the existing market, mandates and regulations, micro & macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

This analysis report similarly presents the information about present on goings, past results and learnings and in future CRISPR Technology business strategies that have been followed by the key players, company extent, reasons of development and time period, share and estimate analysis having a place with the predicted circumstances and situations that may occur. This analysis report similarly reduces the present, past and in future CRISPR Technology business strategies.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-crispr-technology-market-professional-survey-2020-by-manufacturers-regions-types-and-applications-forecast-to-2024

Market segment by Type, the product can be split into

EnzymesKitsgRNALibrariesDesign Tools

Market segment by Application, split into

BiomedicalAgricultural

The CRISPR Technology Market study is major compilation of significant information with respect to the competitor details of this market. The Global CRISPR Technology Market report contains market volume with an accurate estimation offered in the report. Likewise, the information is also inclusive of the several regions where the Global CRISPR Technology Market has successfully gained the position. The Global CRISPR Technology Market report focuses on the major economies, major continents and countries.

The research includes historic data and forecasts which makes the reports a precious supply for the people who are planning to enter into the Global CRISPR Technology Market, executives who look after promotions, consultants of various fields, sales managers, product managers, and many other people considering for significant industry data, willingly accessible documents with deep information on statistics and data presentations through pie charts and graphs which are easy to learn and conclude.

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4459840

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Continue reading here:
Global CRISPR Technology Market Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2024 - Latest Herald

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

New Protein IDed that May Cause Alzheimers

Scientists at the University of Tokyo tested 19,151 individual genes looking for their effect on amyloid beta levels. Amyloid beta is one of the proteins that accumulates in the brains of Alzheimers patients and is generally viewed as one of the primary drivers of the disease. They identified a new protein using CRISPR/Cas9 gene editing, called calcium and integrin-binding protein 1 (CIB1). They found that cells without functional CIB1 genes generate abnormally high levels of amyloid beta protein. The research was published in FASEB Journal.

We believe this is the first time anyone has used this CRISPR/Cas9 genetic screening technique to look for changes in amyloid beta production, said Yukiko Hori, co-first author and lecturer at the University of Tokyo.

In normal, healthy cells, CIB1 is not directly involved with processing amyloid beta, but it stays attached to another protein, gamma secretase inside cells and at the cell membrane. In cells that dont have CIB1, gamma secretase stays inside the cell longer and doesnt leave the membrane. Amyloid beta undergoes multiple steps before reaching its final form. Normally, gamma secretase processes amyloid beta precursors to help produce the final amyloid beta protein. This happens inside the cell, then gamma secretase moves to the cells outer surface membrane.

Patients diagnosed with early-stage Alzheimers disease have lower levels of CIB1 in their brains, while people with late-stage Alzheimers have higher-than-healthy levels of CIB1.

We cannot say for certain why CIB1 is increased in late-stage Alzheimers disease, said Taisuke Tomita, who runs the research lab where the study was conducted. What is important is that in both the early and late stages of Alzheimers disease, something is abnormal about the regulation of CIB1.

Possible Approach to Improving Gene Therapy

Investigators at the University of Groningen have developed a technique that may improve gene therapies. They use DNA/lipid complexes (lipoplexes). Because the viruses used traditionally in gene therapies can cause an immune response and the cells endosomes tend to degrade DNA or other particles, the lipoplex provides protection. They can fuse with the endosome membrane, which prevents degradation.

Gene Promoters that Can Be Used to Treat Neurological Diseases

Researchers at Princeton Neuroscience Institute have developed new gene promoters that act like switches to turn on gene expression. They can be used in gene therapy, with a particular interest in neurological diseases such as Parkinsons and Alzheimers. Viruses are used to carry genes into cells during gene therapy, typically adeno-associated viruses. The Princeton team used promoters found in herpes viruses, which take up less space than existing promoters and allow the transport of larger genes or multiple genes. They are also long-lasting.

Biosensor to Detect SARS-CoV-2 in the Air

Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital have developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air. The work is led by Jing Wang at Empa, who usually works on measuring and analyzing airborne pollutants. The sensor has reliably shown it can identify the first SARS-CoV virus that was responsible for the SARS pandemic in 2003. It has numerous similarities to SARS-CoV-2. Tests showed that the sensor can clearly distinguish between the very similar RNA sequences of the two viruses, Jing Wang said. And the results appear in minutes.

Possible Gene Therapy for Glaucoma

Glaucoma is a common condition of the eye involved fluid buildup in the front part of the eye. It affects more than 64 million people globally and is the leading cause of irreversible blindness. Current treatments include eye drops, laser or surgery. Researchers at the University of Bristol demonstrated that a single injection of a gene therapy using CRISPR and a gene called Aquaporin 1 targeting the ciliary body, where fluid is produced within the eye, led to reduced eye pressure.

More Evidence Parkinsons is an Autoimmune Disease

A study co-led by investigators at the La Jolla Institute for Allergy and Immunology (LJI) adds to the theory that Parkinsons disease is at least partly an autoimmune disease. The research was published in Nature Communications. Science has known for some time that the clumps of a damaged protein known as alpha-synuclein build up in the dopamine-producing brain cells of Parkinsons disease patients. The clumps lead to death of the cells and cause motor symptoms and cognitive decline.

Once these cells are gone, theyre gone, said Cecilia Lindestam Arlehamn, first author of the study and LJI research assistant professor. So if you are able to diagnose the disease as early as possible, it could make a huge difference.

A 2017 study showed that alpha-synuclein attracted certain type of T-cells, causing them to mistakenly attack brain cells, which potentially contributed to the progression of Parkinsons. The new findings found that the T-cells that react to alpha-synuclein are the most abundant when patients are first diagnosed with the disease. They tend to disappear later in the disease and by 10 years after diagnosis, few patients still have them.

This tells us that detection of T-cell responses could help in the diagnosis of people at risk or in early stages of disease development, when many of the symptoms have not been detected yet, said LJI professor Alessandro Sette, who co-led the research with David Sulzer of the Columbia University Medical Center. Importantly, we could dream of a scenario where early interference with T-cell responses could prevent the disease from manifesting itself or progressing.

View original post here:
Research Roundup: New Protein Linked to Alzheimer's Identified and More - BioSpace

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Crispr And Crispr Associated Genes Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Crispr And Crispr Associated Genes market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Crispr And Crispr Associated Genes market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Crispr And Crispr Associated Genes market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Crispr And Crispr Associated Genes Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=202013&utm_source=LHN&utm_medium=888

**Our SAMPLE COPY of the report gives a brief introduction of the Crispr And Crispr Associated Genes market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Crispr And Crispr Associated Genes Market:

Global Crispr And Crispr Associated Genes Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202013&utm_source=LHN&utm_medium=888

Crispr And Crispr Associated Genes Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Crispr And Crispr Associated Genes industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Crispr And Crispr Associated Genes industry.

-> Furthermore, we will help you to identify any crucial trends to predict Crispr And Crispr Associated Genes market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Crispr And Crispr Associated Genes market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=202013&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Crispr And Crispr Associated Genes market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Crispr And Crispr Associated Genes market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Crispr And Crispr Associated Genes Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Crispr And Crispr Associated Genes Market Size, Crispr And Crispr Associated Genes Market Growth, Crispr And Crispr Associated Genes Market Forecast, Crispr And Crispr Associated Genes Market Analysis

Our Trending Reports

Construction Adhesives Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Textile Enzymes Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Acetaldehyde Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See original here:
Crispr And Crispr Associated Genes Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald